Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Radioterapia palliativa monofrazione o multifrazione per il miglioramento della qualità della vita nelle pazienti con tumori ginecologici metastatici

28 ottobre 2026 aggiornato da: M.D. Anderson Cancer Center

Uno studio randomizzato di fase II sulla radioterapia palliativa pelvica per migliorare la qualità della vita correlata alla salute nei tumori maligni ginecologici

This phase II trial studies if a single session of palliative radiation therapy can help improve symptoms of gynecologic cancers that have spread to other places in the body (metastatic) and that affect quality of life as well or more so than multiple sessions (which is the standard of care). Palliative radiation therapy may help patients with metastatic gynecologic cancers live more comfortably. Researchers also want to learn how radiation affects the immune system and to compare the effects of giving one radiation treatment to giving multiple radiation treatments.

Panoramica dello studio

Descrizione dettagliata

PRIMARY OBJECTIVE:

I. To determine whether single fraction palliative radiation therapy (SFRT) improves the proportion of patients with improved Health-Related Quality of Life (HR-QOL) over multi-fraction palliative radiotherapy (MFRT).

SECONDARY OBJECTIVES:

I. To determine whether single fraction palliative radiation therapy (SFRT) improves overall health related quality of life (HR-QOL) over multi fraction palliative radiation therapy (MFRT).

II. To determine whether SFRT improves individual domains of HR-QOL over MFRT.

III. To determine whether SFRT increases clinically meaningful HR-QOL improvement over MFRT.

IV. To determine whether SFRT provides non-inferior symptom burden improvement (SBI) to MFRT.

EXPLORATORY OBJECTIVES:

I. To describe T-cell repertoire of patients receiving SFRT and MFRT.

II. To describe vaginal microbiome of patients receiving SFRT and MFRT.

III. To describe gut microbiome of patients receiving SFRT and MFRT.

IV. To describe financial burden of patients undergoing palliative pelvic radiation with either SFRT or MFRT.

V. To describe financial burden of patients undergoing palliative pelvic radiation with SFRT and MFRT.

OUTLINE: Patients are randomized to 1 of 2 arms.

ARM A: Patients undergo standard of care radiation therapy in the form of 3-dimensional conformal radiation therapy (3D CRT), intensity-modulated radiation therapy (IMRT), or volume modulated arc therapy (VMAT) at the physician's discretion for 1 fraction in the absence of disease progression or unacceptable toxicity. Patients with < 30% decrease in the Symptom Inventory Scale (SIS) may receive an additional fraction on day 21 at the physician's discretion.

ARM B: Patients undergo standard of care radiation therapy in the form of 3D CRT, IMRT, or VMAT at the physician's discretion over 2 weeks for 10 fractions in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up every 3 months for up to 1 year.

Tipo di studio

Interventistico

Iscrizione (Effettivo)

28

Fase

  • Fase 2

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

    • New Jersey
      • Camden, New Jersey, Stati Uniti, 08103
        • Cooper Hospital University
    • Ohio
      • Columbus, Ohio, Stati Uniti, 43215
        • OhioHealth
    • Texas
      • Houston, Texas, Stati Uniti, 77030
        • M D Anderson Cancer Center

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Femmina

Descrizione

Inclusion Criteria:

  • Histologically or cytologically documented gynecologic cancer with prior or current evidence of metastatic disease
  • Measurable pelvic disease with any pain and/or bleeding
  • Eastern Cooperative Oncology Group (ECOG) performance status of =< 3
  • Estimated life expectancy > 3 months at discretion of treating physician
  • Female participants of childbearing potential must be willing to use an adequate method of contraception for the course of the study through 120 days after the last dose of study medication
  • Patient able to provide properly obtained written informed consent
  • Gynecologic Section Radiation Oncology Quality Assurance (QA) for eligibility for single fraction radiation treatment

Exclusion Criteria:

  • Prior pelvic radiation therapy that would make treatment unsafe at the discretion of the treating physician
  • Systemic therapy concurrently or within 21 days of first dose of radiation
  • Concurrent participation in another interventional radiation therapy trial concurrently or within 30 days of study consent. Note: Patients who are participating in systemic clinical trials and non-interventional clinical trials (e.g., QOL, imaging, observational, follow-up studies, etc.) are eligible, regardless of the timing of participation
  • Known second malignancy that requires active treatment (at the discretion of the primary investigator)
  • Documented psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial
  • Pregnant or breastfeeding at any point starting with the pre-screening or screening visit through 120 days after the last dose of trial treatment

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Arm A (radiation therapy)

Patients undergo standard of care radiation therapy in the form of 3D CRT, IMRT, or VMAT at the physician's discretion for 1 fraction in the absence of disease progression or unacceptable toxicity. Patients with < 30% decrease in the SIS may receive an additional fraction on day 21 at the physician's discretion.

Ancillary studies

Altri nomi:
  • Valutazione della qualità della vita

Ancillary studies

Undergo IMRT

Altri nomi:
  • IMRT
  • Intensità modulata RT
  • Radioterapia a intensità modulata
  • Radiazioni, radioterapia a modulazione di intensità

Undergo 3D CRT

Altri nomi:
  • Radioterapia tridimensionale
  • RADIOTERAPIA CONFORME 3D
  • CRT 3D
  • 3D-CRT
  • Terapia Conformazionale
  • Radioterapia conforme
  • Radiazione, conforme 3D

Undergo VMAT

Altri nomi:
  • VMAT
Comparatore attivo: Arm B (radiation therapy)

Patients undergo standard of care radiation therapy in the form of 3D CRT, IMRT, or VMAT at the physician's discretion over 2 weeks for 10 fractions in the absence of disease progression or unacceptable toxicity.

Ancillary studies

Altri nomi:
  • Valutazione della qualità della vita

Ancillary studies

Undergo IMRT

Altri nomi:
  • IMRT
  • Intensità modulata RT
  • Radioterapia a intensità modulata
  • Radiazioni, radioterapia a modulazione di intensità

Undergo 3D CRT

Altri nomi:
  • Radioterapia tridimensionale
  • RADIOTERAPIA CONFORME 3D
  • CRT 3D
  • 3D-CRT
  • Terapia Conformazionale
  • Radioterapia conforme
  • Radiazione, conforme 3D

Undergo VMAT

Altri nomi:
  • VMAT

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Absolute change in index value of EuroQol 5 Dimensions - 5 Levels (EQ-5D-5L) score
Lasso di tempo: Baseline up to 21 days post-radiation therapy

An index value will be calculated for each participant according to page 13 of the user guide. Scores will be summarized using descriptive statistics. Will use a 2-sample t-test to compare the change scores between the single fraction palliative radiation therapy (SFRT) and multi-fraction palliative radiation therapy (MFRT) groups.

Baseline up to 21 days post-radiation therapy

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Absolute change in mobility
Lasso di tempo: Baseline up to 21 days post-radiation therapy

Each dimension is rated on a scale from 1 to 5 where 1 represents no problem present or patient can care for self and 5 represents extreme problems present or unable to care for self. Improvement within each dimension will be assessed by the absolute change of heath state. A decrease in the raw score by 1 or more points denotes improvement within the dimension.

Baseline up to 21 days post-radiation therapy
Absolute change in self-care
Lasso di tempo: Baseline up to 21 days post-radiation therapy

Each dimension is rated on a scale from 1 to 5 where 1 represents no problem present or patient can care for self and 5 represents extreme problems present or unable to care for self. Improvement within each dimension will be assessed by the absolute change of heath state. A decrease in the raw score by 1 or more points denotes improvement within the dimension.

Baseline up to 21 days post-radiation therapy
Absolute change in activity
Lasso di tempo: Baseline up to 21 days post-radiation therapy

Each dimension is rated on a scale from 1 to 5 where 1 represents no problem present or patient can care for self and 5 represents extreme problems present or unable to care for self. Improvement within each dimension will be assessed by the absolute change of heath state. A decrease in the raw score by 1 or more points denotes improvement within the dimension.

Baseline up to 21 days post-radiation therapy
Absolute change in pain
Lasso di tempo: Baseline up to 21 days post-radiation therapy

Each dimension is rated on a scale from 1 to 5 where 1 represents no problem present or patient can care for self and 5 represents extreme problems present or unable to care for self. Improvement within each dimension will be assessed by the absolute change of heath state. A decrease in the raw score by 1 or more points denotes improvement within the dimension.

Baseline up to 21 days post-radiation therapy
Absolute change in anxiety
Lasso di tempo: Baseline up to 21 days post-radiation therapy

Each dimension is rated on a scale from 1 to 5 where 1 represents no problem present or patient can care for self and 5 represents extreme problems present or unable to care for self. Improvement within each dimension will be assessed by the absolute change of heath state. A decrease in the raw score by 1 or more points denotes improvement within the dimension.

Baseline up to 21 days post-radiation therapy
>= 6 point increase in EuroQol-Visual Analogue Scale
Lasso di tempo: Baseline up to 21 days post-radiation therapy

Will summarize the number of patients with clinical meaningful health-related (HR)-quality of life (QOL) improvement using frequencies and proportions. The proportion of patients with clinically meaningful HR-QOL improvement will be compared between SFRT and MFRT using a chi-squared test.

Baseline up to 21 days post-radiation therapy
Decrease in Symptom Inventory (SIS)
Lasso di tempo: At 21 days post-radiation therapy

Will be calculated as the average of the worst pain, least pain, pain on average, pain right now and scores from the vaginal bleeding questions. The change in SIS score from baseline to 21 days post radiation therapy will be calculated for each patient and evaluated between the SFRT and MFRT groups using a t-test. Will be calculated as the average of the worst pain, least pain, pain on average, pain right now and scores from the vaginal bleeding questions. The change in SIS score from baseline to 21 days post radiation therapy will be calculated for each patient and evaluated between the SFRT and MFRT groups using a t-test.

At 21 days post-radiation therapy
Incidence of adverse events
Lasso di tempo: Within 21 days and up to 1 year

Assessed per Common Terminology Criteria for Adverse Events version 5.0. Radiation related toxicity event rates within 21 days and within one year for patients receiving SFRT and MFRT will be summarized using frequencies and proportions. Proportions between SFRT and MFRT will be compared using a chi-squared or Fisher's exact test.

Within 21 days and up to 1 year

Altre misure di risultato

Misura del risultato
Misura Descrizione
Lasso di tempo
T-cell repertoire
Lasso di tempo: Up to 1 year

Will describe T-cell clonality, diversity, clonal overlap, productive and nonproductive frequencies using descriptive statistics. Informal comparisons may be completed to generate hypotheses for future studies.

Up to 1 year
Vaginal microbiome
Lasso di tempo: Up to 1 year

Will use alpha and beta diversity metrics for both 16S and whole-genome sequencing (WGS), including overall diversity, richness and evenness and species-specific microbial dynamics. Will be summarized using descriptive statistics. Informal comparisons may be completed to generate hypotheses for future studies.

Up to 1 year
Gut microbiome
Lasso di tempo: Up to 1 year

Will use alpha and beta diversity metrics for both 16S and WGS sequencing, including overall diversity, richness and evenness and species-specific microbial dynamics. Will be summarized using descriptive statistics. Informal comparisons may be completed to generate hypotheses for future studies.

Up to 1 year
Financial burden
Lasso di tempo: Up to 21 days

Will be assessed using the Economic Strain and Resilience in Cancer Financial Toxicity Questionnaire. The scores for each question will be summarized using descriptive statistics. An overall average score will be calculated by calculating the mean score of the seven questions. At the end of the questionnaire, the patient is asked to rate their overall financial situation as much better, better, nearly the same, worse, or much worse. The frequency of each answer to the global question will be tabulated.

Up to 21 days

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Investigatori

  • Investigatore principale: Lauren Colbert, M.D. Anderson Cancer Center

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

11 gennaio 2021

Completamento primario (Stimato)

31 dicembre 2029

Completamento dello studio (Stimato)

31 dicembre 2029

Date di iscrizione allo studio

Primo inviato

13 agosto 2020

Primo inviato che soddisfa i criteri di controllo qualità

13 agosto 2020

Primo Inserito (Effettivo)

18 agosto 2020

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

30 ottobre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

28 ottobre 2026

Ultimo verificato

1 ottobre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • 2020-0517
  • 2020-0517 (Altro identificatore: M D Anderson Cancer Center)
  • NCI-2020-05684 (Identificatore di registro: CTRP (Clinical Trial Reporting Program))

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

Sì

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi